The first vaccine for the increasingly prevalent chikungunya virus is here

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessions, and offer up your very favorite podcast.

The need-to-know this morning
• Cargo Therapeutics, a developer of CAR-T cell therapies, priced its initial public offering at $15 per share — the low-end of the proposed $15-17 range. The offering raised $281 million.
• Sell-side analyst news: Evercore ISI has hired Cory Kasimov lead research coverage of small- and mid-sized biotech companies. Kasimov spent 15 years at J.P. Morgan before departing in August 2022.
• Illumina reported lower-than-expected third quarter earnings and cut its revenue forecast for the remainder of the year and 2024, citing weaker industry demand for high-end sequencing equipment. The company continues to explore ways to sell its Grail cancer blood test division, following a divestiture order from European regulators.
• Mirati Therapeutics said European regulatory advisers recommended the approval of its KRAS-targeted drug, called Krazati, for the treatment of certain patients with non-small cell lung cancer. The new decision overturned a negative recommendation issued in July. Bristol Myers Squibb is acquiring Mirati for $4.8 billion in a deal announced in October.
• European regulatory advisers recommended an expansion of Eli Lilly’s GLP-1 diabetes drug Mounjaro to include the treatment of obesity.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In